Biotech | August 06, 2021
Mark W. Womack is the new CEO of Stelis Biopharma
He will be stationed at the company HQ in Bengaluru, India
He will be stationed at the company HQ in Bengaluru, India
CDSCO to fast-track trials and approval for COVID19 vaccine
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Subscribe To Our Newsletter & Stay Updated
